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I recently read with great interest the review article “Epidemiology and treatment 
approaches in management of invasive fungal infections” by Kriengkauykiat et al1 
that was published in your journal. This review drew attention to the steadily grow-
ing number of invasive fungal infections (IFIs) that are due to the increasing number 
of severely immunocompromised patients. Despite advances in antifungal regimens 
in terms of prophylaxis and treatment, IFIs may lead to high mortality rates in solid 
organ recipients.
As Kriengkauykiat et al1 mentioned, the incidence of IFIs after kidney trans-
plantation is the lowest of all solid organ transplantations; furthermore, the 
prevalence of IFIs after kidney transplantation in Iran, Turkey, Kuwait, and India   
has been found to be 0.9%, 4%, 3.5%, and 14%, respectively.2 In a large series of 
Iranian kidney transplant recipients, cumulative IFI incidence rate was nearly the 
same as that seen in developed countries (0.87%).2 Although Aspergillus and Can-
dida are responsible for more than 80% of IFIs in organ transplant recipients and 
  zygomycosis represents a small amount of IFIs in kidney transplants (with incidence 
rates of 0.2%–1.2%), in our previous report zygomycosis accounted for 52% of all 
invasive mycoses.2
I agree that the occurrence of IFIs is highest in the first 6 months post-
    transplantation when immunosuppression is most intense. In our recipients, IFIs 
were most likely to occur within 1 year of renal transplantation.2 According to the 
Transplant-Associated Infection Surveillance Network database, most zygomycosis 
infections occurred after the first 3 months after post-hematopoietic cell transplanta-
tion and at a median of 312 days following solid organ transplantation.1 Zygomycosis 
frequently occurs within the first year after kidney transplantation, and is reported 
in 44%–59% of all of kidney transplant patients.3,4
As Kriengkauykiat et al noted, the overall 3-month and 12-month mortality rates 
of zygomycosis in hematopoietic cell transplantation were approximately 64%–72%. 
Moreover, despite being treated with appropriate antifungal agents, the mortality rate 
among kidney transplant patients was as high as 52%, mostly due to zygomycosis.2 In 
addition, in a series of 25 renal recipients with zygomycosis, overall mortality rate was 
52%, particularly in recipients with pulmonary infection (who had a 100% mortality 
rate); however, the mortality rate in those with the rhino-cerebral form of the disease 
was relatively low (31%).4 Early diagnosis of invasive mucormycosis is imperative, 
and must be followed by prompt antifungal and surgical therapy. The mortality rate 
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in patients who received antifungal therapy combined with 
aggressive surgical   debridement as a result of early diagnosis 
was as low as 40%, which contrasts with the 100% mortality 
in those who did not undergo surgery.4
I would like to add the age of recipients to the list of risk 
factors for invasive fungal infections as noted in the review 
article of Kriengkauykiat et al. In a large retrospective study 
of fungal infection in kidney transplant recipients, it was 
found that patient age being greater than 40 was a risk factor 
for invasive fungal infection with zygomycosis.3
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The letter by Einollahi presented very interesting data. 
There were similarities to our review. However, there was a 
significant difference with regard to the proportion of inva-
sive fungal infections caused by Zygomycetes in the Iranian 
renal transplant population (52%)1 compared to reports in 
the literature.2 Perhaps some of the reasons for this differ-
ence may be related to risk factors that may play a role in 
developing zygomycosis, such as diabetes mellitus3 (6/11 in 
the Einollahi et al study1) or the use of antifungal agents 
such as voriconazole or micafungin.4,5 Other possible risk 
factors include iron overload or use of iron chelators such 
as deferoxamine.6,7 It would be interesting to know what 
antifungal agents these patients experienced prior to onset of 
zygomycosis or the presence of other risk factors.
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